cium antagonist or an angiotensin-converting enzyme (ACE) inhibitor? Two papers in this issue of
The risks of treatment are twofold: those that the Journal of Human Hypertension look at some of relate to the fall in BP; and those that relate specifithe irregularly-shaped pieces of this jigsaw puzzle.
cally to the drug which is used. In the context of Damesceno et al 1 examined the efficacy of treatcaptopril, potentially the most important specific ment for hypertensive 'urgencies', where the diasadverse effect is acute renal failure in patients with tolic blood pressure (BP) exceeded 120 mm Hg.
bilateral renal artery stenosis. Nifedipine may or They compared sublingual-oral doses of captopril may not increase cardiac mortality in patients with and standard nifedipine capsules; and in a subcoronary heart disease. 4 A more likely cause of harm study looked at the efficacy of nifedipine-retard in in the context of the hypertensive urgency, however, black patients.
is a propensity to cause hypotensive stroke or myoTreatment of hypertensive urgencies demands a cardial infarction. careful balance between hypertensive damage on the We do not know how variable between individone hand and hypotensive damage on the other. A uals the fall in BP was in the Damesceno study, recent editorial argued that sublingual adminisalthough presumably those who are most likely to tration of standard nifedipine preparations 'for what develop stroke or myocardial infarct as a complioften amounts to blood pressure cosmetics violates cation of treatment are the patients in whom the fall the dictum of primum non nocere.' 2 That particular in BP is especially rapid. The average BP in white dictum is a recipe for therapeutic inaction, because patients fell at a fast rate with sublingual-oral nifedino effective treatment for hypertension, or any other pine capsules, and more gradually with sublingualcondition, will be entirely without risks. It is much oral captopril. That might lead us to prefer the latter. more important to consider the relative risks and
We cannot, however, extrapolate from this single benefits of the various options. Since the risks and comparison to the general statement that ACE benefits may vary from one ethnic group to another, inhibitors are preferable to calcium channel blockstudies examining risks and benefits in two different ing drugs in the management of hypertensive ethnic groups are particularly to be welcomed. urgencies in white subjects. It may be that other calThe trial reported by Damesceno et al 1 found simicium antagonists with slower or more predictable lar falls in BP with the two agents when used to treat absorption would have given different results. It white patients. The initial benefits therefore are may also be that some patients will be at greater risk likely to have been similar. Tbe risks of treatment, of a precipitate drop in BP with captopril than with though, may be different. Because the study was nifedipine. Elderly patients, and those who have small, it could not examine the question of serious high renin concentrations because of diuretic treatbut uncommon adverse effects. Failure to observe an ment, may be especially at risk. 5 In practice, it is event, such as a fatal reaction to treatment, in nine likely to prove difficult to predict who among severpatients (the group size in this study) gives a 95% ely hypertensive white patients will fare better in confidence interval for fatal reactions from none to the short term with a calcium antagonist and who one patient in three, so we cannot be reassured by with an ACE inhibitor. One possible strategy to reduce the rate at which BP falls with nifedipine treatment would be to use a different formulation of nifedipine, although there does not seem to have been a great difference in Correspondence: RE Ferner practice between the results for the two preparations ACE inhibitor, a thiazide, and a calcium channel blocking agent, but this message is attenuated by the in the black patients reported here.
The study re-emphasizes the difference between high drop-out rate. In summary, both ACE inhibitors and calcium hypertension in black and white patients, 6 and the antagonists have a place in the early management of relative inefficacy of ACE inhibitors in black hypertensive urgencies. When treating patients with patients with hypertension. An interesting comparisevere, resistant hypertension, then black patients at son is a study of nifedipine and captopril in least will probably gain more from a strategy where (presumably) subcontinental Indian patients, in the first step is the introduction of a thiazide, which average BP fell from 220/134 to a nadir of although this hypothesis was not formally tested. 164/97 with sublingual nifedipine 10 mg, and from For white patients, the choice will have to be made 226/135 to 176/102 with captopril 25 mg.
7 These on grounds other than antihypertensive efficacy. results are more in keeping with those found in the Thiazides may still be the best initial choice overblack patients studied by Damesceno et al, 1 but the all.
